Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8)

Abstract

Between 1978 and 1983, 44 patients with advanced seminoma were treated with cis-platinum-based combination chemotherapy (39 patients) or with carboplatin (JM8), as a single agent (5 patients). Of the total group, 40 (90%) are alive and disease free. Two of the 4 patients who died relapsed as non-seminomatous germ-cell tumours. Results in previously untreated patients indicate that tumour volume is less important as a prognostic factor than in non-seminomas. Residual masses were present in almost 80% of patients 1 month after chemotherapy; such masses regress slowly and surgery is not indicated. Elective radiotherapy after chemotherapy appears to be inessential since relapse rates are comparable in irradiated (1/15) and unirradiated patients (1/16). Pretreatment serum HCG concentrations did not influence the outcome of chemotherapy. Preliminary results with JM8 suggest that it is an active single agent in the treatment of seminoma.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Peckham, M., Horwich, A. & Hendry, W. Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 52, 7–13 (1985). https://doi.org/10.1038/bjc.1985.141

Download citation

Further reading